Tasigna News and Research

RSS
Sermo announces a new report on evolving trends in CML

Sermo announces a new report on evolving trends in CML

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Researcher develops method for early detection of leukemia relapse

Researcher develops method for early detection of leukemia relapse

Experimental drug SGX393 offers new approach to help control drug resistance in leukemia

Experimental drug SGX393 offers new approach to help control drug resistance in leukemia

Bosutinib safe, effective for chronic myelogenous leukemia

Bosutinib safe, effective for chronic myelogenous leukemia

New drug candidate knocks out resistant form of chronic myeloid leukemia

New drug candidate knocks out resistant form of chronic myeloid leukemia

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

New skin patch treatment for Alzheimer's approved by the European Commission

New skin patch treatment for Alzheimer's approved by the European Commission